Tetrabenazine


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Patient with untreated or inadequately treated depression, actively suicidal, congenital long QT syndromes, history of cardiac arrhythmias; prolactin-dependent tumours (e.g. pituitary or breast cancer). Lactation. Concomitant use within 14 days of discontinuing MAOIs.
Special Precautions
Patient with history of depression or prior suicide attempts or ideation. Patient at risk of aspiration pneumonia. May exacerbate symptoms of parkinsonism. Hepatic impairment. Pregnancy. Patient taking strong CYP2D6 inhibitors. Patient Counselling This drug may cause dizziness, sedation or somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs or symptoms of depression or suicide ideation, parkinsonism, neuroleptic malignant syndrome, orthostatic hypotension. Perform CYP2D6 genotyping for evaluation of metabolism status (doses >50 mg/day).
Adverse Reactions
Significant: Esophageal dysmotility, dysphagia and aspiration; parkinsonism (e.g. bradykinesia, hypertonia, rigidity), akathisia, restlessness, agitation, somnolence (high dose), QTc prolongation, orthostatic hypotension, hyperprolactinaemia. Cardiac disorders: Bradycardia. Gastrointestinal disorders: Dysphagia, nausea, vomiting, diarrhoea, constipation, epigastric pain, dry mouth. Nervous system disorders: Ataxia, dystonia, dizziness, amnesia, tremor, agitation. Psychiatric disorders: Anxiety, insomnia, confusion, disorientation, nervousness. Reproductive system and breast disorders: Irregular menstrual cycle.
Potentially Fatal: Neuroleptic malignant syndrome, suicidal ideation and behaviour.
Drug Interactions
May enhance the adverse effects of tetrabenazine with reserpine. Increased risk of QT prolongation with antipsychotics (e.g. chlorpromazine, thioridazine), antibiotics (e.g. gatifloxacin, moxifloxacin), or class IA and III antiarrhythmics (e.g. quinidine, procainamide, amiodarone, sotalol). May diminish the effect of levodopa. Additive sedative effects with CNS depressants (e.g. neuroleptics, hypnotics, opioids). May increase risk of dopamine depletion and parkinsonism with neuroleptic agents (e.g. haloperidol, metoclopramide, chlorpromazine). May increase risk of orthostatic hypotension with antihypertensive agents (e.g. β-blockers). Increased serum concentrations of the active metabolites of tetrabenazine (α-HTBZ, β-HTBZ) with concomitant use of strong CYP2D6 inhibitors (e.g. fluoxetine, paroxetine, quinidine).
ATC Classification
N07XX06 - tetrabenazine ; Belongs to the class of other nervous system drugs.
Disclaimer: This information is independently developed by CIMS based on tetrabenazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in